ArticleNeurology. Genetics2025
Blood Biomarkers to Identify Renal Angiomyolipomas in People With Tuberous Sclerosis Complex.
Article in Neurology. Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Renal angiomyolipomas (AMLs) affect 80% of people with tuberous sclerosis complex (TSC) during their lifetime. We aimed to determine the diagnostic accuracy of blood biomarkers in identifying the presence and size of renal AMLs in people with TSC. Methods: We collected clinical data and serum samples from individuals followed at 1 TSC clinic (Centre hospitalier de l'Université de Montréal [CHUM] cohort). We also obtained clinical data and plasma samples from participants in the TSC Alliance Natural History Database and Biosample Repository (TSC Alliance cohort). We measured vascular endothelial growth factor D (VEGF-D), kidney injury molecule 1, neutrophil gelatinase-associated lipocalin (NGAL), and cystatin C concentrations in all individuals. We computed receiver operating characteristic curves for each biomarker and determined the optimal thresholds to identify AML vs no AML, and large AML (≥ 3 cm in diameter) vs small/no AML. Results: The CHUM and TSC Alliance cohorts included 41 (23 with AML) and 38 (26 with AML) individuals, respectively. In both cohorts, VEGF-D had the greatest area under the curve, with a sensitivity of at least 0.80 (95% CI 0.49-0.94) and a specificity of at least 0.97 (95% CI 0.83-0.99) in identifying large AML. When VEGF-D and cystatin C were combined, sensitivity increased to 0.96 (95% CI 0.79-0.99) and 1.00 (95% CI 0.72-1.00) for AML presence and size, respectively, in the CHUM cohort. Similar results were observed in a second, independent cohort (the TSC Alliance cohort) when combining VEGF-D and NGAL. Discussion: VEGF-D with either cystatin C or NGAL can accurately screen for large renal AMLs in people with TSC. Smaller renal AMLs can also be screened using these biomarkers, albeit with lower accuracy. Further research is necessary to determine how to implement these biomarkers in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.